Neurology

Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.

If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.

Top news of the day from across the health care landscape.

Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.

Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.

Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.

Top news of the day from across the health care landscape.

Lasmiditan (Reyvow, Eli Lilly) resolved pain and most bothersome symptoms within 2 hours of treatment in patients with migraine.

Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.

The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.

Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.

New updates to immunization guidelines in multiple sclerosis outline recommendations on vaccination decisions for patients.

Dietary interventions that raise levels of high-density lipoprotein, or good cholesterol, may affect fatigue symptoms in multiple sclerosis.

Top news of the day from across the health care landscape.

Rising drug prices for disease-modifying therapies resulted in substantial increases in spending for Medicare beneficiaries with multiple sclerosis.

Patients with progressive multiple sclerosis who were placed on the Wahls diet, which is high in fruits and vegetables, found to experience improved fatigue levels.

The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigourous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.

The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigorous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.

Defining multiple sclerosis helps pinpoint what therapies work best for patients.

Eculizumab (Soliris) is indicated for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.